epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2022-21-2-91-97epidemiology-1527Research ArticleОБЗОРREVIEWВакцинация от COVID-19 пациентов с аллергическими заболеваниями. Позиция врача аллерголога-иммунолога. Обзор литературыVaccination against COVID-19 Patients with Allergic Diseases. The Position of the Allergologist-Immunologist. Literature reviewhttps://orcid.org/0000-0001-5846-851XМаркеловаЕ. В.MarkelovaE. V.

Елена Владимировна Маркелова – д. м. н., профессор, зав. кафедрой

г. Владивосток

+7 (914) 707-85-59

Elena V. Markelova – Dr. Sci. (Med.), Professor, Head department

Vladivostok

markev2010@mail.ruhttps://orcid.org/0000-0003-4571-1749КнышС. В.KnyshS. V.

Сергей Васильевич Кныш – к. м. н., доцент

Москва

+7 (995) 773-65-23

Sergey V. Knysh  – Cand. Sci. (Med.), Associate professor

Moscow

immunolog.vl@gmail.comhttps://orcid.org/0000-0002-1382-9403КостиновМ. П.KostinovM. P.

 Михаил Петрович Костинов – д. м. н., профессор, зав. лабораторией вакцинопрофилактики и иммунотерапии аллергических заболеваний;  зав. кафедрой 

Москва

+7 (495) 917-52-64

Mikhail P. Kostinov – Dr. Sci. (Med.), Professor, Head of laboratory of vaccination and immunotherapy of allergic diseases;  Head of department

Moscow

 

monolit.96@mail.ruФГБОУ ВО Тихоокеанский государственный медицинский университет Минздрава РоссииРоссияPacific state medical universityRussian FederationФГАОУ ВО Первый МГМУ им. И. М. Сеченова Минздрава России (Сеченовский Университет)РоссияSechenov UniversityRussian FederationФГАОУ ВО Первый МГМУ им. И. М. Сеченова Минздрава России (Сеченовский Университет); ФГБНУ «НИИ вакцин и сывороток им. И. И. Мечникова»РоссияMechnikov Research Institute of Vaccines and SeraRussian Federation202211052022212­91­-97Copyright © Маркелова Е.В., Кныш С.В., Костинов М.П., 20222022Маркелова Е.В., Кныш С.В., Костинов М.П.Markelova E.V., Knysh S.V., Kostinov M.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/1527Актуальность

Актуальность. В настоящее время активно продолжается разработка вакцин против COVID-19, их клинические испытания, а также анализируется эффективность используемых вакцин. Очень важным вопросом станет то, как и когда вакцинировать пациентов с различными хроническими заболеваниями, что является относительными и абсолютными противопоказаниями для вакцинации, как различные заболевания могут сказаться на эффективности вакцинации.

Цель

Цель. Представить обзор наиболее значимых опубликованных материалов по вопросу вакцинации от COVID-19 пациентов с аллергическими заболеваниями, а также вероятности развития нежелательных явлений аллергической природы в ответ на введение вакцины.

Выводы

Выводы. Активное изучение вакцин, их эффективности и безопасности демонстрирует нам высокую надежность данных препаратов и отсутствие высоких, по сравнению с иными вакцинами, рисков развития нежелательных явлений. Анафилактические реакции на введение вакцин от COVID-19 встречаются не чаще, чем на любые другие вакцины, используемые в международной медицинской практике.

Relevance

Relevance. Currently, the development of vaccines against COVID-19, their clinical trials are actively continuing, and the effectiveness of the vaccines used is being analyzed. A very important issue will be how and when to vaccinate patients with various chronic diseases, what are the relative and absolute contraindications for vaccination, how various diseases can affect the effectiveness of vaccination.

Aims

Aims. To present an overview of the most significant published materials on the issue of vaccination against COVID19 patients with allergic diseases, as well as the likelihood of developing adverse events of an allergic nature in response to the introduction of the vaccine.

Conclusions

Conclusions. An active study of vaccines, their effectiveness and safety, demonstrates to us the high reliability of these drugs and the absence of high risks of adverse events in comparison with other vaccines. Anaphylactic reactions to the introduction of COVID-19 vaccines are not more common than for any other vaccines used in international medical practice.

вакцинацияCOVID-19аллергиянежелательные явленияастмаобзорvaccinationCOVID-19allergyadverse eventsasthmareviewReferencesWeakly Operational Update on COVID-19. WHO. 2022. I. 93. Доступно на: https://www.who.int/publications/m/item/weekly-operational-update-on-covid19---1-march-2022. Ссылка активна на 21 апреляWeakly Operational Update on COVID-19. WHO. 2022. I. 93. Available at: https://www.who.int/publications/m/item/weekly-operational-update-on-covid19---1-march-2022. Accessed: 21 Apr 2022Dierick BJH, van der Molen T, Flokstra-de Blok BMJ, et al. Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy. Expert Rev Pharmacoecon Outcomes Res. 2020;20(5):437–453. doi:10.1080/14737167.2020.1819793Dierick BJH, van der Molen T, Flokstra-de Blok BMJ, et al. Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy. Expert Rev Pharmacoecon Outcomes Res. 2020;20(5):437–453. doi:10.1080/14737167.2020.1819793Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J. 2014;7(1):12. doi:10.1186/1939-4551-7-12Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J. 2014;7(1):12. doi:10.1186/1939-4551-7-12Moghimi SM. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. Mol Ther. 2021;29(3):898–900. doi:10.1016/j.ymthe.2021.01.030Moghimi SM. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. Mol Ther. 2021;29(3):898–900. doi:10.1016/j.ymthe.2021.01.030Dages KN, Pitlick MM, Joshi AY, Park MA. Risk of allergic reaction in patients with atopic disease and recent coronavirus disease 2019 vaccination. Ann Allergy Asthma Immunol. 2021;127(2):257–258. doi:10.1016/j.anai.2021.04.024Dages KN, Pitlick MM, Joshi AY, Park MA. Risk of allergic reaction in patients with atopic disease and recent coronavirus disease 2019 vaccination. Ann Allergy Asthma Immunol. 2021;127(2):257–258. doi:10.1016/j.anai.2021.04.024Turner PJ, Ansotegui IJ, Campbell DE, et al. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021;14(2):100517. doi:10.1016/j.waojou.2021.100517Turner PJ, Ansotegui IJ, Campbell DE, et al. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021;14(2):100517. doi:10.1016/j.waojou.2021.100517Banerji A, Wolfson AR, Wickner PG, Robnison LB, et al. COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach. // The Journal of Allergy and Clinical Immunology: In Practice. 2021. Vol. 9. I.6. P. 2135–2138. https://doi.org/10.1016/j.jaip.2021.03.053Banerji A, Wolfson AR, Wickner PG, Robnison LB, et al. COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach. The Journal of Allergy and Clinical Immunology: In Practice. 2021. Vol. 9. I.6. P. 2135–2138. https://doi.org/10.1016/j.jaip.2021.03.053Nilsson L, Csuth Á, Storsaeter J, Garvey LH, Jenmalm MC. Vaccine allergy: evidence to consider for COVID-19 vaccines. Curr Opin Allergy Clin Immunol. 2021;21(4):401–409. doi:10.1097/ACI.0000000000000762Nilsson L, Csuth Á, Storsaeter J, Garvey LH, Jenmalm MC. Vaccine allergy: evidence to consider for COVID-19 vaccines. Curr Opin Allergy Clin Immunol. 2021;21(4):401–409. doi:10.1097/ACI.0000000000000762Erdeljic Turk V. Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation. Clin Immunol. 2021;227:108748. doi:10.1016/j.clim.2021.108748Erdeljic Turk V. Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation. Clin Immunol. 2021;227:108748. doi:10.1016/j.clim.2021.108748Klimek L, Novak N, Cabanillas B, et al. Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation. Allergy. 2021;76(11):3307–3313. doi:10.1111/all.14794Klimek L, Novak N, Cabanillas B, et al. Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation. Allergy. 2021;76(11):3307–3313. doi:10.1111/all.14794Park HJ, Montgomery JR, Boggs NA. Anaphylaxis After the Covid-19 Vaccine in a Patient With Cholinergic Urticaria [published online ahead of print, 2021 Apr 14]. Mil Med. 2021;usab138. doi:10.1093/milmed/usab138Park HJ, Montgomery JR, Boggs NA. Anaphylaxis After the Covid-19 Vaccine in a Patient With Cholinergic Urticaria [published online ahead of print, 2021 Apr 14]. Mil Med. 2021;usab138. doi:10.1093/milmed/usab138Kadali RAK, Janagama R, Peruru S, et al. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol. 2021;93(7):4420–4429. doi:10.1002/jmv.26996Kadali RAK, Janagama R, Peruru S, et al. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol. 2021;93(7):4420–4429. doi:10.1002/jmv.26996Shavit R, Maoz-Segal R, Iancovici-Kidon M, et al. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk. JAMA Netw Open. 2021;4(8):e2122255. doi:10.1001/jamanetworkopen.2021.22255Shavit R, Maoz-Segal R, Iancovici-Kidon M, et al. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk. JAMA Netw Open. 2021;4(8):e2122255. doi:10.1001/jamanetworkopen.2021.22255Wolfson AR, Robinson LB, Li L, et al. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. J Allergy Clin Immunol Pract. 2021;9(9):3308–3320.e3. doi:10.1016/j.jaip.2021.06.010Wolfson AR, Robinson LB, Li L, et al. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. J Allergy Clin Immunol Pract. 2021;9(9):3308–3320.e3. doi:10.1016/j.jaip.2021.06.010Pfaar O, Klimek L, Hamelmann E, et al. COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) - A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA). Allergol Select. 2021;5:140–147. doi:10.5414/ALX02241EPfaar O, Klimek L, Hamelmann E, et al. COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) - A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA). Allergol Select. 2021;5:140–147. doi:10.5414/ALX02241EМагаршак О. О., Костинов М. П. Проблемы вакцинации детей с аллергическими заболеваниями. Лечащий врач. 2008. № 9. С. 44–48.Magarshak OO, Kostinov MP. Problemy vakcinacii detej s allergicheskimi zabolevanijami. Lechashhij vrach. 2008;9:44–48 (In Russ.).Ильина Н. И., Курбачева О. М., Латышева Е. А. и др. Вакцинация пациентов с аллергическими заболеваниями против новой коронавирусной инфекции COVID-19: позиционный документ Российской ассоциации аллергологов и клинических иммунологов. Российский аллергологический журнал. - 2021. - Т. 18. - №3. - C. 93–97. doi: 10.36691/RJA1479Ilyina NI, Kurbacheva OM, Latysheva EA, Latysheva TV, et al. Vaccination of patients with allergic disease against novel coronavirus infection: position paper of the Russian Association of Allergology and Clinical Immunology. Russian Journal of Allergy. 2021;18(3):93–97(In Russ.). doi: 10.36691/RJA1479Костинов М. П. Вакцинация взрослых – от стратегии к тактике. Руководство для врачей. М.: МДВ, 2020.Kostinov MP, Adult vaccination – from strategy to tactics. A guide for doctors. M: MDV, 2020 (In Russ.).Костинов М.П., Гервазиева В.Б., Балаболкин И.И., Максимова Н.М., Переверзева Н.В. Вакцинопрофилактика дифтерии и столбняка у детей, страдающих бронхиальной астмой и астматическим бронхитом. Журнал микробиологии, эпидемиологии и иммунобиологии. 1993;(3):76–80.Kostinov MP, Gervazieva VB, Balabolkin II, Maksimova NM, et al. Vaktsinoprofilaktika difterii i stolbniaka u deteĭ, stradaiushchikh bronkhial’noĭ astmoĭ i astmaticheskim bronkhitom [The vaccinal prevention of diphtheria and tetanus in children suffering from bronchial asthma and asthmatic bronchitis]. Zhurnal mikrobiologii, epidemiologii i immunobiologii 1993;(3):76–80 (In Russ.).Thyssen JP, Vestergaard C, Barbarot S, et al. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. J Eur Acad Dermatol Venereol. 2021;35(5):e308–e311. doi:10.1111/jdv.17167Thyssen JP, Vestergaard C, Barbarot S, et al. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. J Eur Acad Dermatol Venereol. 2021;35(5):e308–e311. doi:10.1111/jdv.17167Nittner-Marszalska M, Rosiek-Biegus M, Kopeć A, et al. Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals. Vaccines (Basel). 2021;9(6):553. Published 2021 May 25. doi:10.3390/vaccines9060553Nittner-Marszalska M, Rosiek-Biegus M, Kopeć A, et al. Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals. Vaccines (Basel). 2021;9(6):553. Published 2021 May 25. doi:10.3390/vaccines9060553Johnston MS, Galan A, Watsky KL, Little AJ. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series. JAMA Dermatol. 2021;157(6):716–720. doi:10.1001/jamadermatol.2021.1214Johnston MS, Galan A, Watsky KL, Little AJ. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series. JAMA Dermatol. 2021;157(6):716–720. doi:10.1001/jamadermatol.2021.1214Rasmussen, TH, Mortz, CG, Georgsen, TK, Rasmussen, HM, Kjaer, HF, Bindslev-Jensen, C. Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up. Clin Transl Allergy. 2021;e12044. https://doi.org/10.1002/clt2.12044Rasmussen, TH, Mortz, CG, Georgsen, TK, Rasmussen, HM, Kjaer, HF, Bindslev-Jensen, C. Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up. Clin Transl Allergy. 2021;e12044. https://doi.org/10.1002/clt2.12044Greenhawt M, Abrams EM, Shaker M, et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. // J Allergy Clin Immunol Pract. 2021;9(10):3546–3567. doi:10.1016/j.jaip.2021.06.00623. Greenhawt M, Abrams EM, Shaker M, et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract. 2021;9(10):3546–3567. doi:10.1016/j.jaip.2021.06.006

The authors declare that there are no conflicts of interest present.